Traders Buy Eli Lilly and Company (LLY) on Weakness

Investors purchased shares of Eli Lilly and Company (NYSE:LLY) on weakness during trading hours on Monday. $45.06 million flowed into the stock on the tick-up and $19.57 million flowed out of the stock on the tick-down, for a money net flow of $25.49 million into the stock. Of all equities tracked, Eli Lilly and had the 33rd highest net in-flow for the day. Eli Lilly and traded down ($0.03) for the day and closed at $87.05

Several analysts recently weighed in on LLY shares. UBS AG cut shares of Eli Lilly and to a “hold” rating and set a $85.00 price objective on the stock. in a research note on Wednesday, July 26th. BMO Capital Markets reissued a “sell” rating and issued a $71.00 price objective on shares of Eli Lilly and in a research note on Thursday, September 28th. Jefferies Group LLC reissued a “buy” rating and issued a $93.00 price objective on shares of Eli Lilly and in a research note on Thursday, June 22nd. Morgan Stanley set a $86.00 price objective on shares of Eli Lilly and and gave the stock a “hold” rating in a research note on Friday, October 6th. Finally, Berenberg Bank reissued a “buy” rating and issued a $98.00 price objective on shares of Eli Lilly and in a research note on Friday, August 4th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have given a buy rating to the company’s stock. Eli Lilly and currently has an average rating of “Hold” and a consensus target price of $88.57.

The company’s 50 day moving average price is $82.75 and its 200 day moving average price is $82.15. The stock has a market cap of $90.90 billion, a price-to-earnings ratio of 37.28 and a beta of 0.34.

Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.06. The business had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The company’s revenue was up 7.8% on a year-over-year basis. During the same quarter last year, the firm earned $0.86 EPS. Equities analysts expect that Eli Lilly and Company will post $4.16 EPS for the current fiscal year.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 180,000 shares of the firm’s stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $81.06, for a total value of $14,590,800.00. Following the sale, the insider now owns 123,865,804 shares of the company’s stock, valued at approximately $10,040,562,072.24. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In the last three months, insiders sold 990,000 shares of company stock worth $82,949,650. Insiders own 0.20% of the company’s stock.

Institutional investors have recently made changes to their positions in the business. Acrospire Investment Management LLC grew its holdings in Eli Lilly and by 16.7% in the 2nd quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock worth $115,000 after acquiring an additional 200 shares during the last quarter. MPS Loria Financial Planners LLC bought a new stake in Eli Lilly and in the 2nd quarter worth $128,000. San Francisco Sentry Investment Group CA bought a new stake in Eli Lilly and in the 2nd quarter worth $129,000. Heritage Trust Co bought a new stake in Eli Lilly and in the 1st quarter worth $135,000. Finally, Point72 Asia Hong Kong Ltd grew its holdings in Eli Lilly and by 237.4% in the 1st quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock worth $148,000 after acquiring an additional 1,239 shares during the last quarter. 75.72% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Traders Buy Eli Lilly and Company (LLY) on Weakness” was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at https://sportsperspectives.com/2017/10/11/traders-buy-eli-lilly-and-company-lly-on-weakness.html.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply